PRESS INFORMATION
13 December 2002
ELEMENTIS plc TRADING UPDATE
Elementis today issues a trading update ahead of the preliminary results for the year ending 31 December 2002.
Overall market demand continues to be flat and, as expected, sales for the year will be below the equivalent period
last year. In particular, strong pricing pressure in Elementis Chromium has increased during the second half of the
year. Cost control discipline has been effectively applied throughout Elementis and as expected, underlying operating
profit for 2002 will be well above the 2001 level, albeit slightly below current market expectations.
During the second half of the year, a number of actions have been taken to improve financial performance and drive the
growth strategy outlined earlier this year.
The acquisition of OxyChem's chromium chemicals business was completed on 6 December, and integration is progressing.
Rationalisation of the manufacturing operations at Corpus Christi is underway, which will provide identified cost
saving benefits in 2003, significantly improving Elementis Chromium's competitive position in the Americas.
An investment of £10 million has been approved for a basic pigments manufacturing facility at a new site in Taicang,
near Shanghai, China. The new wholly-owned plant will produce technically advanced products for the Asia-Pacific
market and is expected to be commissioned in 2004.
The strategic review of the Elementis Pigments operation at Birtley in the northeast of England concluded that the site
will remain operational but will be significantly restructured to improve profitability. The commodity zinc business
will be closed resulting in the loss of around 65 jobs. An exceptional charge of £4.5 million will be taken in 2002
and the closure is expected to be complete during the first quarter of 2003.
In a further move to refine the Elementis Pigments' product portfolio, the sale of the US based anhydrous aluminium
chloride catalyst business for £1.7 million, announced in July 2002, has been completed.
Elementis Specialties has opened a new manufacturing facility in Chanxing, near Nanjing, China to produce organoclays
for the rapidly expanding Chinese and Asian markets. The new venture manufactures organoclays from local raw materials,
and is presently undergoing upgrading and expansion work that will be completed in early 2003.
The Enterprise Resource Planning programme, started in June, is progressing on time and within budget. Global
implementation will commence in the second quarter of 2003.
The preliminary results announcement will be made on 27 February 2002.
- Ends -
There will be an analyst conference call today at 1000 GMT on +44 20 8240 8244 with the reference Elementis. This call
will be hosted by Geoff Gaywood, Chief Executive and Brian Taylorson, Finance Director.
Enquiries
Elementis +44 (0) 1784 224212
Geoff Gaywood Chief Executive
Brian Taylorson Finance Director
Anna Passey Head of Corporate Communications
Brunswick +44 (0) 20 7404 5959
Andrew Fenwick
Fiona Fong
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.